The Effect of the Cytoprotector Rebamipid on the Activity of Disaccharidases in Patients with Enteropathy with Impaired Membrane Digestion

ENMP (enteropathy with impaired membrane digestion) is a new nosological form of pathology of the small intestine, which is based on a decrease in the activity of small intestine carbohydraz. The clinical picture of ENMA is very similar to irritable bowel syndrome, but it differs in the etiotropic relationship of symptoms with intolerance to products containing a lot of fermentable oligo -, di- and monosaccharides and polyols. The basis of the treatment of this pathology is the FODMAP diet, but this therapy only allows you to reduce the load on the enzymatic transport complexes, and not restore them. A new direction in the treatment of patients with EMF is our proposed system for restoring the activity of enzymes of the small intestine mucosa under the influence of the cytoprotector rebamipid. The use of rebamipid in the complex therapy of INMP contributes to an increase in the activity of small intestine carbohydraz and a decrease in symptoms associated with intolerance to short-chain carbohydrates FODMAP. The persistent positive effect of the drug is observed gradually over 8 weeks in patients who received the drug at a dose of 300 mg/day. With this treatment regimen, patients have an improvement in the tolerability of carbohydrate-containing foods, a decrease in flatulence, pain syndrome, and a tendency to normalize the stool has also been noted.